Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

3251 - 3260 of 3488 results found

Treatment of Hypertension in Adults Over Age 60 to Higher vs. Lower Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

MeSH Terms
Blood Pressure (G09.330.380.076); Pharmacologic Actions (D27.505); Angiotensin-Converting Enzyme Inhibitors (D27.505.519.389.745.085); Angiotensin Receptor Antagonists (D27.505.519.162); Antihypertensive Agents (D27.505.954.411.162); Calcium Channel Blockers (D27.505.954.411.192); Calcium Channel Blockers (D27.505.519.562.249); Adrenergic beta-1 Receptor Antagonists (D27.505.696.577.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.696.577.050.100.200.100); Adrenergic beta-1 Receptor Antagonists (D27.505.519.625.050.200.200.100); Adrenergic beta-1 Receptor Agonists (D27.505.519.625.050.100.200.100); Adrenergic beta-2 Receptor Agonists (D27.505.519.625.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.519.625.050.200.200.200); Adrenergic beta-2 Receptor Agonists (D27.505.696.577.050.100.200.200); Adrenergic beta-2 Receptor Antagonists (D27.505.696.577.050.200.200.200); Adrenergic beta-3 Receptor Agonists (D27.505.519.625.050.100.200.300); Adrenergic beta-3 Receptor Agonists (D27.505.696.577.050.100.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.519.625.050.200.200.300); Adrenergic beta-3 Receptor Antagonists (D27.505.696.577.050.200.200.300); Hypertension (C14.907.489); Blood Pressure (E01.370.600.875.249)
Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
17/01/2022
Publication Scope
management
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
AAFP (US)
ACP (US)
Publication Year
2017

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

MeSH Terms
Vitamin D (D04.808.812.768); Women (M01.975); Osteoporosis (C05.116.198.579); Pharmacologic Actions (D27.505); Therapeutic Uses (D27.505.954); Alendronate (D02.705.429.500.100); Peptide Hormones (D06.472.699); Peptide Hormones (D12.644.548); Teriparatide (D06.472.699.590.850); Teriparatide (D12.644.548.587.850); Calcitonin (D06.472.699.150); Calcitonin (D12.644.400.095); Calcitonin (D12.644.548.150); Calcitonin (D12.776.641.650.095); Estrogen Replacement Therapy (E02.319.452.150); Selective Estrogen Receptor Modulators (D27.505.696.399.450.360.827); Selective Estrogen Receptor Modulators (D06.347.360.827); Raloxifene (D02.455.426.559.389.150.700.900.775); Osteoporosis; Postmenopausal (C05.116.198.579.610); Calcium (D01.268.552.100); Calcium (D01.552.539.288)
Guideline Contact
Amir Qaseem (aqaseem@acponline.org)
Date for Review
2006-06-22
Publication Scope
prevention
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ACP (US)
Publication Year
2017

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

MeSH Terms
Multiple Myeloma (C04.557.595.500); Stem Cell Transplantation (E04.936.225.687); Maintenance Chemotherapy (E02.319.509)
Guideline Contact
guidelines@asco.org
Expected Publication Date
01-Apr-19
Publication Scope
management
treatment
Countries of Application
Canada
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
Publication Year
2019

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline

MeSH Terms
Urinary Bladder Neoplasms (C04.588.945.947.960)
Guideline Contact
guidelines@asco.org
Publication Date
10-Aug-17
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
ASTRO (US)
Publication Year
2017